JNJ

227.48

-1.23%↓

ABBV

210.79

-0.05%↓

UNH

391.64

-2.14%↓

AZN

181.98

-1.84%↓

NVS

148.18

-1.5%↓

JNJ

227.48

-1.23%↓

ABBV

210.79

-0.05%↓

UNH

391.64

-2.14%↓

AZN

181.98

-1.84%↓

NVS

148.18

-1.5%↓

JNJ

227.48

-1.23%↓

ABBV

210.79

-0.05%↓

UNH

391.64

-2.14%↓

AZN

181.98

-1.84%↓

NVS

148.18

-1.5%↓

JNJ

227.48

-1.23%↓

ABBV

210.79

-0.05%↓

UNH

391.64

-2.14%↓

AZN

181.98

-1.84%↓

NVS

148.18

-1.5%↓

JNJ

227.48

-1.23%↓

ABBV

210.79

-0.05%↓

UNH

391.64

-2.14%↓

AZN

181.98

-1.84%↓

NVS

148.18

-1.5%↓

Начало・Списък с акции・Eli Lilly and Co.

Eli Lilly and Co.

Отворен

СекторЗдравеопазване

1,001.96 -0.61

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

997

Максимум

1013.94

Ключови измерители
By Trading Economics
Приходи	758M 7.4B
Продажби	507M 20B
P/E Средно за сектора	34.327 51.415
EPS	8.55
Дивидентна доходност	0.66
Марж на печалбата	37.355
Служители	50,000
EBITDA	971M 9.4B

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+25.44% upside

Дивиденти
By Dow Jones
Дивидентна доходност Средно за сектора	0.66% 2.34%
Следващи печалби	5.08.2026 г.
Следваща дата на дивидент	10.06.2026 г.
Следваща дата на екс-дивидент	15.05.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	87B 862B
Предишно отваряне	1002.57
Предишно затваряне	1001.96

Настроения в новините

By Acuity

33%

67%

93 / 346 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

N/A / 884.54 Подкрепа & съпротива

Eli Lilly and Co. Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

30.04.2026 г., 12:01 ч. UTC

Печалби

Значими двигатели на пазара

Eli Lilly Shares Jump On Guidance Boost, Earnings Above Expectations

7.05.2026 г., 09:30 ч. UTC

Печалби

America's Weight-Loss Drug Boom Is Going Global -- Heard on the Street -- WSJ

6.05.2026 г., 12:36 ч. UTC

Печалби

Novo's Weight-Loss Pill Heaps Pressure on Eli Lilly. Stock Jumps After Earnings. -- Barrons.com

6.05.2026 г., 10:12 ч. UTC

Печалби

Novo Stock Rises After Earnings. It's Taking the Weight-Loss Drug Fight to Eli Lilly. -- Barrons.com

6.05.2026 г., 09:58 ч. UTC

Печалби

Novo Nordisk Shares Jump on Strong Demand for Wegovy Pill -- 2nd Update

30.04.2026 г., 20:59 ч. UTC

Горещи акции

Stocks to Watch Recap: Blue Owl, Alphabet, Qualcomm, Meta Platforms -- WSJ

30.04.2026 г., 20:12 ч. UTC

Печалби

Eli Lilly Stock Jumps on Earnings Beat as Zepbound and Mounjaro Sales Skyrocket -- Barrons.com

30.04.2026 г., 16:43 ч. UTC

Печалби

Eli Lilly Shares Jump 10% as Mounjaro, Zepbound Fuel Massive Growth -- WSJ

30.04.2026 г., 16:10 ч. UTC

Пазарно говорене

Eli Lilly Expecting A Push to Extend Medicare GLP-1 Coverage -- Market Talk

30.04.2026 г., 15:13 ч. UTC

Печалби

Update: Eli Lilly Stock Jumps on Earnings Beat as Zepbound and Mounjaro Sales Skyrocket -- Barrons.com

30.04.2026 г., 14:58 ч. UTC

Печалби

Lilly CEO: Direct-to-Consumer Channel Popularity Will Continue, Become Useful in Other Kinds of Drugs

30.04.2026 г., 14:53 ч. UTC

Печалби

Lilly Expects Government to Push to Get GLP-1 Medicare Coverage for 2028, CEO Says

30.04.2026 г., 14:50 ч. UTC

Печалби

Lilly Expects Strong Persistence in Medicare Population for GLP-1s, President of Lilly USA Says

30.04.2026 г., 14:42 ч. UTC

Печалби

Gaining Incremental Market Share in GLP-1s Getting Harder, President of Lilly International Says

30.04.2026 г., 14:39 ч. UTC

Печалби

Lilly CEO: GLP-1 Unit Economics Dependent on Fixed Costs Unmoved by Volume

30.04.2026 г., 14:35 ч. UTC

Печалби

Lilly CEO: GLP-1 Price Cuts Result in Large Volume Expansions

30.04.2026 г., 14:24 ч. UTC

Печалби

Lilly to Begin Full-Scale Consumer Promotion, Including TV Ads, of Foundayo in 3Q, CFO Says

30.04.2026 г., 14:17 ч. UTC

Печалби

Lilly CFO: Loss of Medicaid Access in Some States Hurt 1Q Prescription Growth By High Single Digits

30.04.2026 г., 13:56 ч. UTC

Печалби

Eli Lilly Stock Jumps on Earnings Beat as Zepbound and Mounjaro Sales Skyrocket -- Barrons.com

30.04.2026 г., 13:37 ч. UTC

Горещи акции

Stocks to Watch: Alphabet, Qualcomm, Meta Platforms, Eli Lilly -- WSJ

30.04.2026 г., 12:32 ч. UTC

Пазарно говорене

Печалби

Eli Lilly CEO Says Early Foundayo Results Are Strong -- Market Talk

30.04.2026 г., 12:29 ч. UTC

Пазарно говорене

Печалби

Eli Lilly CEO Says Foundayo Adoption Could Take Time -- Market Talk

30.04.2026 г., 12:23 ч. UTC

Пазарно говорене

Печалби

Eli Lilly CEO Says International Demand for GLP-1s Is Ramping Up -- Market Talk

30.04.2026 г., 12:10 ч. UTC

Печалби

Eli Lilly Stock Jumps on Earnings Beat as Zepbound and Mounjaro Sales Skyrocket -- Barrons.com

30.04.2026 г., 12:08 ч. UTC

Печалби

Eli Lilly Sales, Profits Surge on Weight-Loss Drugs -- WSJ

30.04.2026 г., 12:04 ч. UTC

Пазарно говорене

Печалби

Eli Lilly's GLP-1 Party Has No End in Sight -- Market Talk

30.04.2026 г., 11:39 ч. UTC

Горещи акции

Stocks to Watch: Alphabet, Qualcomm, Meta Platforms, Eli Lilly -- WSJ

30.04.2026 г., 11:08 ч. UTC

Печалби

Eli Lilly Stock Jumps on Earnings Beat as Zepbound and Mounjaro Sales Skyrocket -- Barrons.com

30.04.2026 г., 10:50 ч. UTC

Печалби

Eli Lilly Raises 2026 Performance Margin View to 47%-48.5% From 46%-47.5% >LLY

30.04.2026 г., 10:49 ч. UTC

Печалби

Eli Lilly Had Seen 2026 Revenue $80B-$83B, Adjusted EPS $33.50-$35.00 >LLY

Сравнение с други в отрасъла

Ценова промяна

Eli Lilly and Co. Прогноза

Ценова цел

By TipRanks

25.44% нагоре

12-месечна прогноза

Среден 1,262.85 USD 25.44%

Висок 1,500 USD

Нисък 850 USD

Според 22 анализатори от Wall Street, предложили 12-месечна ценова цел за Eli Lilly and Co. през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

22 ratings

Купи

Задържане

Продай

Според 22 анализатори, дали борсови рейтинги на Eli Lilly and Co. през последните 3 месеца.

Техническа оценка

By Trading Central

N/A / 884.54Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Настроение

By Acuity

93 / 346 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Eli Lilly and Co.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It operates Lilly Seaport Innovation Center (LSC), a research and development facility in the Boston Seaport to advancing Lilly's efforts in RNA and DNA-based therapies as well as discovering new drug targets to create life-changing medicines across several disease states, including diabetes, obesity, cardiovascular diseases, neurodegeneration, and chronic pain. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; and Chugai Pharmaceutical Co., Ltd, as well as development collaboration with Eli Lilly and Company for developing QIAstat-Dx IVD panel, for the detection of various APOE genotypes. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.